| Product name: |
TGF2 rabbit pAb |
| Reactivity: |
Human;Mouse;Rat |
| Alternative Names: |
Transforming growth factor beta-2 (TGF-beta-2;BSC-1 cell growth inhibitor;Cetermin;Glioblastoma-derived T-cell suppressor factor;G-TSF;Polyergin) |
| Source: |
Rabbit |
| Dilutions: |
WB 1:500-2000,IHC-p 1:500-200, ELISA 1:10000-20000 |
| Immunogen: |
The antiserum was produced against synthesized peptide derived from human TGF beta2. AA range:361-410 |
| Storage: |
-20C/1 year |
| Clonality: |
Polyclonal |
| Isotype: |
IgG |
| Concentration: |
1 mg/ml |
| Observed Band: |
47+12kD |
| GeneID: |
7042 |
| Human Swiss-Prot No: |
P61812 |
| Cellular localization: |
[Latency-associated peptide]: Secreted, extracellular space, extracellular matrix .; [Transforming growth factor beta-2]: Secreted . |
| Background: |
This gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Ligands of this family bind various TGF-beta receptors leading to recruitment and activation of SMAD family transcription factors that regulate gene expression. The encoded preproprotein is proteolytically processed to generate a latency-associated peptide (LAP) and a mature peptide, and is found in either a latent form composed of a mature peptide homodimer, a LAP homodimer, and a latent TGF-beta binding protein, or in an active form consisting solely of the mature peptide homodimer. The mature peptide may also form heterodimers with other TGF-beta family members. Disruption of the TGF-beta/SMAD pathway has been implicated in a variety of human cancers. A chromosomal translocation that includes this gene is associated with Peters’ anomaly, a congenital defect of the an |
